title: Genetic polymorphism on endothelial nitric oxide synthase affects endothelial activation and inflammatory response during the acute phase of myocardial infarction.
abstract: OBJECTIVE
  This study sought to evaluate the effect of genetic polymorphism G894T on endothelial nitric oxide synthase (eNOS); on the risk for myocardial infarction (MI); and on the release of von Willebrand factor (vWF), interleukin (IL)-6, IL-1b, and oxidized low-density lipoprotein (ox-LDL) levels during the acute phase of MI and one year after the event.
  
  
  BACKGROUND
  Genetic polymorphism G894T on eNOS has been associated with increased cardiovascular risk. However, its role during the acute phase of MI is unknown.
  
  
  METHODS
  The study population consisted of 228 patients with a first event of premature MI and 519 matched control patients. One year after the event, 61 patients and 205 control patients were recalled for the follow-up study. Blood sampling was performed during the acute phase and after one year.
  
  
  RESULTS
  The risk for MI in 894TT was 1.992 (95% confidence interval [CI], 1.131 to 3.485), p < 0.05 versus GG+GT; 2.038 (95% CI, 1.125 to 3.695), p < 0.05 versus GG; and 2.009 (95% CI, 1.106 to 3.651), p < 0.05 versus GT. During the acute phase, vWF was higher in GT+TT (121.02 +/- 5.47%) versus GG (84.6 +/- 7.1%, p < 0.01), an effect persisting after one year (90.4 +/- 3.8 vs. 73.1 +/- 4.6%, p < 0.01). During the acute phase, GT+TT had higher ox-LDL and IL-6 (131.2 +/- 6.4 IU/l and 8.5 +/- 0.7 pg/ml) compared with GG (101.7 +/- 9.64 IU/l and 6.2 +/- 0.8 pg/ml, p < 0.05 for both), but no difference was found at one year.
  
  
  CONCLUSIONS
  G894T polymorphism on the eNOS gene increases the risk for premature MI and modifies the response of vascular endothelium during the acute phase of MI by affecting the release of vWF, IL-6, and oxidative stress status, an effect diminished one year after the event.
authors.affiliation: Cardiology Department, Athens University Medical School, Hippokration Hospital, Athens, Greece.
authors.forename: Charalambos
authors.initials: C
authors.lastname: Antoniades
authors.forename: Dimitris
authors.initials: D
authors.lastname: Tousoulis
authors.forename: Carmen
authors.initials: C
authors.lastname: Vasiliadou
authors.forename: Christos
authors.initials: C
authors.lastname: Pitsavos
authors.forename: Christina
authors.initials: C
authors.lastname: Chrysochoou
authors.forename: Demosthenis
authors.initials: D
authors.lastname: Panagiotakos
authors.forename: Costas
authors.initials: C
authors.lastname: Tentolouris
authors.forename: Kyriakoula
authors.initials: K
authors.lastname: Marinou
authors.forename: Nikolaos
authors.initials: N
authors.lastname: Koumallos
authors.forename: Christodoulos
authors.initials: C
authors.lastname: Stefanadis
mesh_terms: D005260:Female; D006801:Humans; D007249:Inflammation; D007375:Interleukin-1 / Q000097:blood; D015850:Interleukin-6 / Q000097:blood; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009203:Myocardial Infarction / Q000201:enzymology / Q000235:genetics* / Q000276:immunology* / Q000378:metabolism; D052250:Nitric Oxide Synthase Type III / Q000235:genetics*; D018384:Oxidative Stress; D011110:Polymorphism, Genetic; D014841:von Willebrand Factor / Q000032:analysis
chemical_list: D007375:Interleukin-1; D015850:Interleukin-6; D014841:von Willebrand Factor; D052250:Nitric Oxide Synthase Type III